^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Margenza (margetuximab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Published date:
04/25/2023
Excerpt:
ctDNA analysis was performed retrospectively using plasma samples collected at study entry from 86 patients participating in the phase 1/2 CP-MGAH22-05 study...Objective response rate (ORR) was significantly higher in evaluable ERBB2 amplification-positive vs - negative patients based on ctDNA analysis at study entry (37% vs 6%, respectively; P = .00094). ORR was 23% across all patients who were evaluable for response...Current ERBB2 status may be more effective than archival status at predicting clinical benefit from margetuximab plus pembrolizumab therapy.
DOI:
10.46883/2023.25920992
Trial ID:
Source:
Title:
BIOMARKER-GUIDED ENRICHMENT OF THE ANTITUMOR ACTIVITY OF MARGETUXIMAB (M) PLUS PEMBROLIZUMAB (P) IN PATIENTS WITH ADVANCED HER2+ GASTRIC ADENOCARCINOMA (GEA)
Published date:
10/21/2018
Excerpt:
The presence of ERBB2 amplification by ctDNA and tumor PD-L1 expression by IHC were both associated with increased probability of OR: 33.3% v. 10.5% (p = 0.0948) and 43.8% v. 16.7% (p = 0.0769), respectively. ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts
DOI:
10.1093/annonc/mdy282
Trial ID:
